Item 2.02 - Results of Operations and Financial Condition: Company issued a press release on February 12, 2026 reporting consolidated financial results for the three and twelve months ended December 31, 2025 Item 9.01 - Financial Statements and Exhibits: Press release reporting Q4 2025 and full year 2025 financial results is attached as Exhibit 99.1 Filing Date: February 12, 2026 (earliest event…

Our analysis rates this filing BULLISH. Vertex Pharmaceuticals demonstrates a fundamentally bullish profile with strong positive momentum substantially outweighing identified concerns. The company achieved a dramatic earnings turnaround (from $536M loss to $4.0B profit), raised 2026 guidance, and…

Concern level: MODERATE (2.8/10). Key factors: Revenue concentration risk: CF portfolio represents 96.1-96.2% of total revenue ($12.45-12.6B of $12.95-13.1B guidance), creating vulnerability to CF market headwinds despite strong current performance; Modest 2026 guidance growth: +8.5% midpoint growth vs. 2025 represents deceleration from 2025's +9% YoY performance, suggesting CF market maturation…

Notable risk changes: Strong financial performance: FY2025 total revenue $12.0B (+9% YoY), GAAP net income $4.0B vs. $(536)M loss in 2024, driven by CF portfolio strength and new product launches; Positive pipeline advancement: ALYFTREK pediatric (ages 2-5) study completed with 'unprecedented results' for age group; povetacicept BLA filing for IgAN expected H1 2026; multiple mid/late-stage programs advancing; Modest…

No explicit earnings surprise data disclosed in filing (analyst consensus comparisons not provided).

The model predicts VRTX will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.